Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

640
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
640

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma.

Cancer research·2026
Same author

Quantifying single-cell responses to irradiation in 3D.

Frontiers in bioengineering and biotechnology·2026
Same author

Cell Cycle-Specific Regulation of Centrosome Clustering Dynamics in Cancer Cells by the Multifunctional Kinesin HSET.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Genetic resonance in the p53 signaling network.

Cell systems·2026
Same author

DNA damage checkpoints balance a tradeoff between diploid- and polyploid-derived arrest failures.

Cell reports·2025
Same author

Decoding the Central Dogma: Quantitative Insights into Transcription and Translation Dynamics in the p53-Mediated DNA Damage Response.

Journal of molecular biology·2025
Same journal

A native sulfur deposit in Gale crater, Mars.

Science (New York, N.Y.)·2026
Same journal

Coordinated demise of harmful algal blooms.

Science (New York, N.Y.)·2026
Same journal

Genetic effects put into context.

Science (New York, N.Y.)·2026
Same journal

Bacteria share proteins to survive antibiotics.

Science (New York, N.Y.)·2026
Same journal

Impacts shaped Earth's first continents.

Science (New York, N.Y.)·2026
Same journal

Erratum for the Report "Covalently bonded single-molecule junctions with stable and reversible photoswitched conductivity" by C. Jia <i>et al</i>.

Science (New York, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: Mar 24, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K

Schedule-dependent interaction between anticancer treatments.

Sheng-Hong Chen1, William Forrester2, Galit Lahav1

  • 1Department of Systems Biology, Harvard Medical School, Boston, MA, USA.

Science (New York, N.Y.)
|March 12, 2016
PubMed
Summary
This summary is machine-generated.

Inhibiting the oncogene MDMX reactivates tumor suppressor p53, but its effect on cancer cell death depends on p53

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.6K

Related Experiment Videos

Last Updated: Mar 24, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.9K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • The oncogene MDMX is overexpressed in many cancers, suppressing the tumor suppressor p53.
  • MDMX inhibitors may reactivate p53 and enhance DNA-damaging drug efficacy.
  • A quantitative understanding of MDMX inhibition's effect on p53 signaling and DNA damage sensitivity is lacking.

Purpose of the Study:

  • To quantitatively investigate how MDMX inhibition affects the p53 signaling pathway.
  • To determine the impact of MDMX inhibition on cancer cell sensitivity to DNA-damaging agents.

Main Methods:

  • Live cell imaging was employed to observe p53 accumulation dynamics in single cells following MDMX depletion.
  • The study analyzed the differential responses of cells to DNA damage during distinct phases of p53 accumulation.

Main Results:

  • MDMX depletion induced two distinct phases of p53 accumulation: an initial postmitotic pulse and subsequent low-amplitude oscillations.
  • Cellular response to DNA damage varied significantly between these phases.
  • In the first phase, MDMX depletion synergized with DNA damage to induce cell death.
  • In the second phase, MDMX depletion inhibited DNA damage-induced cell death.

Conclusions:

  • The timing of MDMX inhibition relative to DNA damage is critical for therapeutic outcomes.
  • Understanding p53 signal dynamics and cellular states is essential for optimizing combination therapies.
  • This research provides a quantitative basis for scheduling dual-drug administration involving MDMX inhibitors and DNA-damaging agents.